A single shot of engineered DNA turned obese mice into their own factory for a long-acting weight-loss drug.
That is the result behind a paper published online June 19 in Trends in Biotechnology ↗ from David Weiner's group at the Wistar Institute in Philadelphia, with collaborators at the University of Pennsylvania, Inovio Pharmaceuticals, and several other labs. Instead of injecting the drug, they injected a plasmid, a small ring of DNA carrying the instructions to build it, and let the animals' own cells do the manufacturing.
The drugs everyone knows are peptides. Semaglutide (Ozempic and Wegovy ↗) and tirzepatide (Mounjaro and Zepbound ↗) are short protein chains that have to be manufactured at scale, shipped cold, and injected every week because the body clears them quickly. That weekly cadence, and the supply chain behind it, are two of the field's real bottlenecks. The idea here is to skip both by handing the body the gene instead of the protein.
How it works
The team built what they call pLincretins, short for plasmid-launched incretins. Each plasmid encodes a GLP-1 and a GIP analogue, the two gut hormones that signal fullness after a meal, engineered to resist the enzymes that normally chew them up, and fused to a fragment of an antibody (the Fc region) that keeps the product circulating longer. They delivered the DNA into diet-induced obese mice with an electroporation device, a brief electric pulse that opens cells to take up DNA, already validated in human trials for other uses.
One administration was enough. The mice expressed the engineered incretin steadily and showed durable drops in body weight, food intake, and blood glucose. Durability is the whole point. Plasmid DNA has already been shown to make functional antibodies in human patients for more than a year from a single dose, and that antibody precedent is the reason to take the incretin version seriously rather than file it as another mouse curiosity.
The designed molecule
The second half is where the computation comes in. Rather than copy an existing hormone, the team used AI-guided protein modeling and a synthetic consensus approach, which blends many natural sequence variants into one optimized design, to build a dual GLP-1 and GIP receptor agonist they call pSynCretin. It bound the GLP-1 receptor more tightly than the natural sequence and drove potent weight loss in the mice. Tirzepatide is also a dual GLP-1/GIP agonist, which makes pSynCretin a DNA-launched run at the same two-receptor strategy that is currently the most effective on the market.
The caveats
This is a mouse study, and the gap between a diet-induced obese mouse and a human patient has swallowed many promising metabolic drugs. A gene that keeps making a drug is also harder to switch off than a weekly injection you simply stop taking, which matters if side effects appear, and the long-term safety of sustained incretin expression is exactly what a mouse paper cannot answer. Inovio, one of the collaborators, has spent years on DNA-delivery platforms with a mixed clinical record.
Still, the framing is worth holding onto. The current GLP-1 era runs on peptides that are expensive to make and have to be re-injected forever. A version the body manufactures from a single dose would change both the economics and the compliance math, if it survives the move out of mice. peptidemodel hosts the cards for the incretin drugs this is trying to leapfrog, and the DNA-launched approach aims squarely at their biggest practical weakness, which is that you have to keep taking them.